MOUNTAIN VIEW, Calif., Dec. 3, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that senior management will present an overview of the company at two investment conferences during the month of December.
The conference presentation schedule is as follows:
Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
December 8, 2010 at 12:30 p.m. PT
Nikko Hotel, San Francisco, CA
Presenter: Charles Bowden, MD, director of clinical development
2010 Deutsche Bank BioFEST Conference
December 14, 2010 at 4:05 p.m. ET
Four Seasons Hotel, Boston, MA
Presenter: Timothy Morris, chief financial officer
A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
The Trout Group
Timothy E. Morris
Chief Financial Officer
SOURCE VIVUS, Inc.